Stereotactic Radiosurgery for Brain Metastases from Lung Cancer
Trial Summary
What is the purpose of this trial?
The purpose of the study is to see if stereotactic radiosurgery/SRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer/SCLC.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Stereotactic Radiosurgery for brain metastases from lung cancer?
Research shows that Stereotactic Radiosurgery (SRS) is effective in prolonging survival for patients with a single brain metastasis and maintaining functional independence for those with up to three brain metastases. It is a precise treatment option that has become standard for patients with few metastatic brain lesions, offering an alternative to whole brain radiation therapy.12345
Is stereotactic radiosurgery (SRS) safe for humans?
How does the treatment Stereotactic Radiosurgery (SRS) for brain metastases from lung cancer differ from other treatments?
Stereotactic Radiosurgery (SRS) is unique because it delivers a highly focused, single session of radiation directly to the brain metastases, minimizing exposure to surrounding healthy tissue. This approach reduces the need for invasive surgery and avoids the broader side effects associated with whole brain radiation therapy.12111213
Research Team
Luke Pike, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Eligibility Criteria
This trial is for adults with small cell lung cancer that has spread to the brain. They must be able to consent, have a good performance status (able to carry out daily activities), and women must not be pregnant. People can't join if they've had previous brain radiotherapy, are pregnant or breastfeeding, can't undergo MRI scans, or have uncontrolled systemic disease.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive stereotactic radiosurgery (SRS) for brain metastases from small cell lung cancer
Follow-up
Participants are monitored for overall survival and effectiveness of the treatment
Treatment Details
Interventions
- Stereotactic Radiosurgery
Stereotactic Radiosurgery is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:
- Brain tumors
- Metastatic brain tumors
- Arteriovenous malformations (AVMs)
- Trigeminal neuralgia
- Acoustic neuromas
- Brain tumors
- Metastatic brain tumors
- Arteriovenous malformations (AVMs)
- Trigeminal neuralgia
- Acoustic neuromas
- Liver tumors
- Lung tumors
- Spinal cord tumors
- Brain tumors
- Metastatic brain tumors
- Arteriovenous malformations (AVMs)
- Trigeminal neuralgia
- Acoustic neuromas
- Brain tumors
- Metastatic brain tumors
- Arteriovenous malformations (AVMs)
- Trigeminal neuralgia
- Acoustic neuromas
- Brain tumors
- Metastatic brain tumors
- Arteriovenous malformations (AVMs)
- Trigeminal neuralgia
- Acoustic neuromas
- Brain tumors
- Metastatic brain tumors
- Arteriovenous malformations (AVMs)
- Trigeminal neuralgia
- Acoustic neuromas
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor